Last, because IL-35 has been involved in induction of IL-10 and of the co-inhibitory molecules PD1, TIM3, and LAG3 (8), that are known to be expressed in DLBCL and can impact the patient outcome (38–41), we investigated whether increased expression of IL-35 was associated with increased expression of IL-10, PD1 (PDCD1), TIM3 (HAVCR2), or LAG3 in these patients (Figures 7B,D). Here, IL10 is linked to diffuse large B-cell lymphoma.